US$ 29.87
noom and glp 1 Med Noom to offer GLP-1 drug
Description
Diabetes Obes Metab (2016) 18(6):5819

doi: 10.2337/diabetes.50.3.609

Novo Nordisk "is on the cusp of evergreening its obesity franchise beyond Ozempic/Wegovy through new innovation (drugs like Amycretin, Cagri-Sema), which could see it drive towards a $1 trillion valuation," Pot said

The first thing you will notice from this chart is that it includes information that allows you to convert from T4-only medication to NDT medication to T3-only medication to synthetic T4 + T3 combinations
